Bifogade filer
No. 5 Resolutions passed at the Extraordinary General Meeting of Chr. Hansen Holding AS
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL.
MARCH 30, 2023 – COMPANY ANNOUNCEMENT NO. 5
At the Extraordinary General Meeting of Chr. Hansen Holding A/S (“Chr. Hansen”) held on Thursday March 30, 2023, the following proposals as set out in detail in the convening notice were adopted:
- Resolution to adopt the implementation of a statutory merger of Chr. Hansen and Novozymes A/S (“Novozymes”) in accordance with the merger plan of December 12, 2022.
The implementation of the statutory merger of Chr. Hansen and Novozymes was also adopted by the Novozymes shareholders at an Extraordinary Shareholders’ Meeting of Novozymes held earlier today. The completion of the merger remains subject to the satisfaction of a number of conditions, including certain regulatory approvals, and certain termination rights as further described in the exemption document published on March 8, 2023. The exemption document is available (with certain restriction) via the websites listed below.
- Resolution to approve transaction specific indemnification of management and relevant employees.
The full text of the approved indemnification is included in the convening notice published as company announcement no. 4 of March 8, 2023.
- Change of the financial year of Chr. Hansen to follow the calendar year.
Financial reporting for the period until December 31, 2023, will continue in accordance with the existing financial calendar.
- Adjustment of Board remuneration due to proposed merger and change of financial year.
- Authorization to the Chair of the Extraordinary General Meeting.
For additional information on the proposed combination, please visit www.power-with-biology.com or www.chr-hansen.com/en/investors/proposed-merger.
Please see attachment.
For further information please contact:
Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364
Sanne Seyer-Hansen, Head of Press Relations, Tel: +45 6038 6207
About Chr. Hansen
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. At Chr. Hansen, we are well positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends, we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world's most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.